1. Home
  2. SCWO vs MOLN Comparison

SCWO vs MOLN Comparison

Compare SCWO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$2.86

Market Cap

45.2M

Sector

Utilities

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.69

Market Cap

158.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCWO
MOLN
Founded
2021
2004
Country
United States
Switzerland
Employees
27
N/A
Industry
Environmental Services
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
45.2M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SCWO
MOLN
Price
$2.86
$4.69
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
45.4K
4.1K
Earning Date
04-02-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5,945.19
N/A
Revenue Next Year
$106.82
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$3.36
52 Week High
$3.55
$5.36

Technical Indicators

Market Signals
Indicator
SCWO
MOLN
Relative Strength Index (RSI) 57.18 51.34
Support Level $2.35 $3.51
Resistance Level $3.10 $5.33
Average True Range (ATR) 0.22 0.27
MACD 0.02 -0.06
Stochastic Oscillator 74.73 46.82

Price Performance

Historical Comparison
SCWO
MOLN

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: